FDA approves new oral drug to relieve constipation from opioid painkillers

Share this article:
Long-term care residents who experience constipation from taking opioids to manage chronic pain may benefit from Amitiza, an oral drug recently approved by the Food and Drug Administration.

Amitiza (lubiprostone) has already been approved in the United States for other conditions, such as constipation-related irritable bowel syndrome. Manufactured by Sucampo Pharmaceuticals Inc./Takeda Pharmaceuticals USA Inc., it is the first oral drug to relieve constipation caused by opioid therapy for managing noncancer pain.

Constipation is a common side effect for people who take oxycodone, fentanyl or other opioids on a long-term basis. Amitiza was approved by the FDA based on 12-week studies of people on these painkillers.

The drug's effectiveness when taken with diphenylheptane opioids, such as methadone, has not been established, according to the manufacturer. The company also warned that lubiprostone should not be taken by anyone with impaired liver function.

Share this article:

More in News

Hospitals in the Midwest refer patients to the broadest networks of skilled nursing facilities, study finds

Hospitals in the Midwest refer patients to the ...

Midwestern hospitals spread referrals to the greatest variety of skilled nursing facilities and tap their favorite SNFs least often, according to a recently published analysis of nationwide referral patterns.

Bill would affect pay, scheduling for some nursing home housekeeping staff

Nursing homes could face more stringent scheduling requirements for housekeeping workers and might be on the hook to compensate them for last-minute shift changes under a bill proposed in both houses of Congress.

Joint Commission adds memory care accreditation

New memory care accreditation for nursing homes encourages staff to use a flexible, problem-solving approach to care for those with dementia, according to Joint Commission guidelines.